| abstract |
Antibody polypeptides that specifically bind to a new human CD40 epitope are provided. The antibody polypeptides show no CD40 agonist activity. Antibody polypeptides are useful in the treatment of disorders that involve the activation of CD40, such as autoimmune disorders. The antibody polypeptides may be domain antibodies (dAbs) that comprise a single domain of VL or VH. The half-life of the antibody polypeptides can be increased by modification of the antibody polypeptides to be specific double reagents that can also be cross-linked to human serum albumin (HSA). |